Omissions – Commissions – Errors – Blunders – Solithromycin
![](https://i0.wp.com/allphasepharma.com/dir/wp-content/uploads/2017/01/Solithro-Ketek-slider.jpg?resize=640%2C180&ssl=1)
Cempra received a complete response letter (CRL) as a X-mas present from FDA, and the news was pretty bad for company investors. Bad, but not totally unexpected after the AMDAC meeting last November, which taught us a few new things Continue reading Omissions – Commissions – Errors – Blunders – Solithromycin